NanoEcho AB (publ) (STO:NANECH)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0400
-0.0012 (-2.91%)
At close: May 20, 2026
Market Cap18.30M -41.1%
Revenue (ttm)649.00K -89.4%
Net Income-15.58M
EPS-0.05
Shares Out457.54M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,549,923
Average Volume3,131,227
Open0.0410
Previous Close0.0412
Day's Range0.0362 - 0.0494
52-Week Range0.0200 - 0.1800
Betan/a
RSI51.64
Earnings DateApr 30, 2026

About NanoEcho AB

NanoEcho AB (publ) engages in developing a new diagnostic method to determine the spread of rectal cancer to nearby lymph nodes. The company was incorporated in 2013 and is headquartered in Lund, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol NANECH
Full Company Profile

Financial Performance

In 2025, NanoEcho AB's revenue was 487,000, a decrease of -93.30% compared to the previous year's 7.27 million. Losses were -15.65 million, 3.35% more than in 2024.

Financial Statements

News

NanoEcho AB Quarterly report: Q1 2026

NanoEcho AB has published its Q1 2026 quarterly earnings report on April 30, 2026.

21 days ago - Filings

NanoEcho AB Annual report: Q4 2025

NanoEcho AB has published its Q4 2025 annual report on February 12, 2026.

3 months ago - Filings

NanoEcho AB Quarterly report: Q4 2025

NanoEcho AB has published its Q4 2025 quarterly earnings report on February 12, 2026.

3 months ago - Filings

NanoEcho AB Quarterly report: Q3 2025

NanoEcho AB has published its Q3 2025 quarterly earnings report on October 23, 2025.

7 months ago - Filings

NanoEcho AB Quarterly report: Q2 2025

NanoEcho AB has published its Q2 2025 quarterly earnings report on August 21, 2025.

9 months ago - Filings

NanoEcho AB Earnings Call Transcript: Q2 2024

Transitioned to clinical phase after completing product development and regulatory milestones. Net loss increased to SEK 8.7 million with no revenue, but a successful rights issue secured 12 months of capital for clinical trials. Market approval is targeted for H2 2027.

1 year ago - Transcripts